Free Papers

Vector analysis of the efficacy of the myopic astigmatic correction achieved with a new topography-integrated wavefront-guided LASIK procedure

Free Paper Details

First Author: A.Uceda IRELAND

Co Author(s):    M. Rogers   D. Piñero Llorens                 

Abstract Details

Purpose:

To evaluate the efficacy of the myopic astigmatic correction achieved with laser in situ keratomileusis (LASIK) using a new approach for the calculation of the ablation profile based on wavefront vertexing from pupil plane to corneal.

Setting:

Optilase Eye Clinics, Dublin, Ireland

Methods:

Prospective consecutive case series enrolling 100 eyes of 50 patients (age, 21-41 years) with myopic astigmatism. All of them underwent topography-integrated wavefront-guided (TI-WFG) LASIK using the STAR S4IR excimer laser platform (Johnson & Johnson Vision). Visual and refractive outcomes were evaluated after a 90-day follow-up period, including an Alpins vector analysis of astigmatic changes.

Results:

The magnitude of manifest sphere and cylinder was reduced significantly with surgery (p<0.001), with the corresponding significant improvement in uncorrected visual acuity (UDVA) (p<0.001). No significant changes in the magnitude of error of astigmatic correction were detected during the follow-up, with a mean value of -0.04±0.24 D at 90 days postoperatively (p=0.005). Likewise, no significant changes during the follow-up were detected in surgically induced astigmatism and correction index at 90 days after surgery, with mean values of 0.65±0.43 D and 1.01±0.56, respectively. Concerning the angle of error, a significant reduction was observed during the follow-up, with a mean value at 90 days after surgery of 0.17±0.18º.

Conclusions:

TI-WFG LASIK provides a very predictable correction of myopic astigmatism, with no trend to over or undercorrection.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented